Rachel King

Currently holds positions in Novavax Inc and Crescent Biopharma Inc

2.3

4.2

4.4

Position	Company	Period
Independent Director	Novavax Inc	Nov. 1, 2018 -
President, Chief Executive Officer, Co-Founder, Director	Crescent Biopharma Inc	Jan. 1, 2003 -

• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings

Download results Settings

Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other

Notification date	Transaction date	Company	B/S Transaction type	Nb. shares Price Value	Number of shares	Price	Value
2025-01-02	2024-12-13	Novavax Inc (NVAX)	S Sale	29,934 -5.7% 394.76 US$1,614,262	29,934 -5.7%	394.76	US$1,614,262
2024-12-13	2024-12-13	Novavax Inc (NVAX)	PrS Proposed sale	13,310 239.64 US$4,308,516	13,310	239.64	US$4,308,516
2021-05-21	2021-05-19	Novavax Inc (NVAX)	B Purchase	13,689 +3.6% 352.96 US$4,447,351	13,689 +3.6%	352.96	US$4,447,351
2020-12-30	2020-12-28	Crescent Biopharma Inc (CBIO)	PlS Planned sale	84,176 -19.1% 3.91 US$329,128	84,176 -19.1%	3.91	US$329,128
2019-03-28	2019-03-27	Novavax Inc (NVAX)	B Purchase	22,000 +inf% 0.53 US$11,656	22,000 +inf%	0.53	US$11,656
2019-03-28	2019-03-27	Novavax Inc (NVAX)	B Purchase	22,000 +inf% 0.53 US$11,656	22,000 +inf%	0.53	US$11,656
2019-03-28	2019-03-27	Novavax Inc (NVAX)	B Purchase	42,000 +inf% 0.53 US$22,252	42,000 +inf%	0.53	US$22,252